Home
»
Press Room
»
Pharma 4.0 Market Size To Reach $61.7 Billion By 2033

Pharma 4.0 Market Size To Reach $61.7 Billion By 2033

April 2026 | Report Format: Electronic (PDF)

Pharma 4.0 Market Growth & Trends

The global pharma 4.0 market size is expected to reach USD 61.7 billion by 2033, registering a CAGR of 19.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.

In addition, increasing adoption of digital technologies is driving the market growth. These technologies optimize, improve, and revolutionize drug development, manufacturing, distribution, and patient care. Blockchain technology has significantly reshaped supply chain management by offering transparency, traceability, and optimization, reducing stockouts, preventing counterfeiting, and enhancing overall efficiency and patient safety.

Furthermore, the market growth is being driven by increasing investments from pharmaceutical companies in adopting Pharma 4.0 technologies. For example, AstraZeneca signed a deal worth up to USD 840 million for the target identification of rare neurodegenerative and neuromuscular diseases. As part of this deal, AstraZeneca’s Alexion division will collaborate with Verge Genomics to identify drug targets for these conditions. Over the course of the four-year, multi-target agreement, the companies will utilize machine learning to analyze Verge’s genomic datasets, which are derived from human tissue rather than cell or animal models.

key Request a free sample copy or view report summary: Pharma 4.0 Market Report

Pharma 4. 0 Market Report Highlights

The software segment held the largest market share of 55.8% in 2025. The demand for software solutions in the pharmaceutical industry is increasing as companies seek to harness advanced digital technologies to enhance efficiency, innovation, and compliance across their operations.
The AI/ML segment held the largest market share of 32.7% in 2025. Artificial Intelligence (AI) presents substantial opportunities for pharmaceutical manufacturers by improving process design, control, smart monitoring, and maintenance, ultimately driving continuous improvement.
The drug discovery and development segment accounted for the largest market share of 40.0% in 2025.
Based on the end use, the pharma & biotech segment held the largest market share of 49.7% in 2025. Pharmaceutical companies are increasingly adopting Pharma 4.0 technologies to enhance efficiency, productivity, and quality across their manufacturing and R&D processes.
North America dominated the pharma 4.0 market with a revenue share of 43.1% in 2025. The growth is driven by technological advancements and the need for increased efficiency and compliance within the pharmaceutical industry.